618 related articles for article (PubMed ID: 33787832)
1. Cost-effectiveness of Treatments for Opioid Use Disorder.
Fairley M; Humphreys K; Joyce VR; Bounthavong M; Trafton J; Combs A; Oliva EM; Goldhaber-Fiebert JD; Asch SM; Brandeau ML; Owens DK
JAMA Psychiatry; 2021 Jul; 78(7):767-777. PubMed ID: 33787832
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Buprenorphine-Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse.
Murphy SM; McCollister KE; Leff JA; Yang X; Jeng PJ; Lee JD; Nunes EV; Novo P; Rotrosen J; Schackman BR
Ann Intern Med; 2019 Jan; 170(2):90-98. PubMed ID: 30557443
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care.
Schackman BR; Leff JA; Polsky D; Moore BA; Fiellin DA
J Gen Intern Med; 2012 Jun; 27(6):669-76. PubMed ID: 22215271
[TBL] [Abstract][Full Text] [Related]
4. Estimated effectiveness and cost-effectiveness of opioid use disorder treatment under proposed U.S. regulatory relaxations: A model-based analysis.
Qian G; Humphreys K; Goldhaber-Fiebert JD; Brandeau ML
Drug Alcohol Depend; 2024 Mar; 256():111112. PubMed ID: 38335797
[TBL] [Abstract][Full Text] [Related]
5. Estimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts.
Chatterjee A; Weitz M; Savinkina A; Macmadu A; Madushani RWMA; Potee RA; Ryan D; Murphy SM; Walley AY; Linas BP
JAMA Netw Open; 2023 Apr; 6(4):e237036. PubMed ID: 37058306
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of full and partial opioid agonists for opioid use disorder in outpatient settings: United States healthcare sector perspective.
Choi SA; Yan CH; Gastala NM; Touchette DR; Stranges PM
J Subst Use Addict Treat; 2024 May; 160():209237. PubMed ID: 38061629
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Injectable Extended-Release Naltrexone Compared With Methadone Maintenance and Buprenorphine Maintenance Treatment for Opioid Dependence.
Jackson H; Mandell K; Johnson K; Chatterjee D; Vanness DJ
Subst Abus; 2015; 36(2):226-31. PubMed ID: 25775099
[TBL] [Abstract][Full Text] [Related]
8. A comparison of adherence, outcomes, and costs among opioid use disorder Medicaid patients treated with buprenorphine and methadone: A view from the payer perspective.
Kinsky S; Houck PR; Mayes K; Loveland D; Daley D; Schuster JM
J Subst Abuse Treat; 2019 Sep; 104():15-21. PubMed ID: 31370980
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of Increasing Buprenorphine Treatment Initiation, Duration, and Capacity Among Individuals Who Use Opioids.
Claypool AL; DiGennaro C; Russell WA; Yildirim MF; Zhang AF; Reid Z; Stringfellow EJ; Bearnot B; Schackman BR; Humphreys K; Jalali MS
JAMA Health Forum; 2023 May; 4(5):e231080. PubMed ID: 37204803
[TBL] [Abstract][Full Text] [Related]
10. Methadone, Buprenorphine, or Detoxification for Management of Perinatal Opioid Use Disorder: A Cost-Effectiveness Analysis.
Premkumar A; Grobman WA; Terplan M; Miller ES
Obstet Gynecol; 2019 Nov; 134(5):921-931. PubMed ID: 31599845
[TBL] [Abstract][Full Text] [Related]
11. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.
Wakeman SE; Larochelle MR; Ameli O; Chaisson CE; McPheeters JT; Crown WH; Azocar F; Sanghavi DM
JAMA Netw Open; 2020 Feb; 3(2):e1920622. PubMed ID: 32022884
[TBL] [Abstract][Full Text] [Related]
12. Healthcare utilization and costs associated with treatment for opioid dependence.
Shah A; Duncan M; Atreja N; Tai KS; Gore M
J Med Econ; 2018 Apr; 21(4):406-415. PubMed ID: 29320915
[TBL] [Abstract][Full Text] [Related]
13. Modeling the cost-effectiveness and impact on fatal overdose and initiation of buprenorphine-naloxone treatment at syringe service programs.
Adams JW; Savinkina A; Fox A; Behrends CN; Madushani RWMA; Wang J; Chatterjee A; Walley AY; Barocas JA; Linas BP
Addiction; 2022 Oct; 117(10):2635-2648. PubMed ID: 35315148
[TBL] [Abstract][Full Text] [Related]
14. Opioid use disorder in Germany: healthcare costs of patients in opioid maintenance treatment.
Reimer J; Vogelmann T; Trümper D; Scherbaum N
Subst Abuse Treat Prev Policy; 2019 Dec; 14(1):57. PubMed ID: 31842942
[TBL] [Abstract][Full Text] [Related]
15. Association of Opioid Use Disorder Treatment With Alcohol-Related Acute Events.
Xu KY; Presnall N; Mintz CM; Borodovsky JT; Bhat NR; Bierut LJ; Grucza RA
JAMA Netw Open; 2021 Feb; 4(2):e210061. PubMed ID: 33625511
[TBL] [Abstract][Full Text] [Related]
16. Cardiac and mortality outcome differences between methadone, buprenorphine and naltrexone prescriptions in patients with an opioid use disorder.
Wang L; Volkow ND; Berger NA; Davis PB; Kaelber DC; Xu R
J Clin Psychol; 2023 Dec; 79(12):2869-2883. PubMed ID: 37584532
[TBL] [Abstract][Full Text] [Related]
17. Economic Evaluation in Opioid Modeling: Systematic Review.
Beaulieu E; DiGennaro C; Stringfellow E; Connolly A; Hamilton A; Hyder A; Cerdá M; Keyes KM; Jalali MS
Value Health; 2021 Feb; 24(2):158-173. PubMed ID: 33518022
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of buprenorphine vs. methadone for pregnant people with opioid use disorder.
Robin AM; Hersh AR; John C; Caughey AB
J Matern Fetal Neonatal Med; 2022 Dec; 35(25):4918-4926. PubMed ID: 33455473
[TBL] [Abstract][Full Text] [Related]
19. Medication Treatment of Opioid Use Disorder.
Bell J; Strang J
Biol Psychiatry; 2020 Jan; 87(1):82-88. PubMed ID: 31420089
[TBL] [Abstract][Full Text] [Related]
20. Management of opioid-dependent patients: comparison of the cost associated with use of buprenorphine/naloxone or methadone, and their interactions with concomitant treatments for infectious or psychiatric comorbidities.
Roncero C; Domínguez-Hernández R; Díaz T; Fernández JM; Forcada R; Martínez JM; Seijo P; Terán A; Oyagüez I
Adicciones; 2015 Sep; 27(3):179-89. PubMed ID: 26437312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]